Adewole S Adamson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3110318/publications.pdf

Version: 2024-02-01

58 papers	1,319 citations	516710 16 h-index	377865 34 g-index
58 all docs	58 docs citations	58 times ranked	1904 citing authors

#	Article	IF	Citations
1	Machine Learning and Health Care Disparities in Dermatology. JAMA Dermatology, 2018, 154, 1247.	4.1	281
2	The Rapid Rise in Cutaneous Melanoma Diagnoses. New England Journal of Medicine, 2021, 384, 72-79.	27.0	224
3	The Current STATus of lymphocyte signaling: new roles for old players. Current Opinion in Immunology, 2009, 21, 161-166.	5.5	101
4	Machine Learning and the Cancer-Diagnosis Problem â€" No Gold Standard. New England Journal of Medicine, 2019, 381, 2285-2287.	27.0	69
5	UV Exposure and the Risk of Cutaneous Melanoma in Skin of Color. JAMA Dermatology, 2021, 157, 213.	4.1	61
6	Association of Delays in Surgery for Melanoma With Insurance Type. JAMA Dermatology, 2017, 153, 1106.	4.1	58
7	Signal transduction and Th17 cell differentiation. Microbes and Infection, 2009, 11, 599-611.	1.9	52
8	Reframing racial and ethnic disparities in atopic dermatitis in Black and Latinx populations. Journal of Allergy and Clinical Immunology, 2021, 148, 1104-1111.	2.9	40
9	Geographic Distribution of Nonphysician Clinicians Who Independently Billed Medicare for Common Dermatologic Services in 2014. JAMA Dermatology, 2018, 154, 30.	4.1	27
10	Commentary: Position statement on augmented intelligence (AuI). Journal of the American Academy of Dermatology, 2019, 81, 998-1000.	1.2	27
11	Time's up to adopt a biopsychosocial model to address racial and ethnic disparities in asthma outcomes. Journal of Allergy and Clinical Immunology, 2019, 143, 2024-2025.	2.9	25
12	Medicare Part D Payments for Topical Steroids. JAMA Dermatology, 2017, 153, 755.	4.1	24
13	Twitter Journal Clubs. JAMA Dermatology, 2020, 156, 729.	4.1	23
14	Estimating Overdiagnosis of Melanoma Using Trends Among Black and White Patients in the US. JAMA Dermatology, 2022, 158, 426.	4.1	22
15	Patient-provider race and sex concordance and the risk for medication primary nonadherence. Journal of the American Academy of Dermatology, 2017, 76, 1193-1195.	1.2	19
16	Systemic Absorption of Sunscreen. JAMA - Journal of the American Medical Association, 2020, 323, 223.	7.4	19
17	An Antiracist Framework for Racial and Ethnic Health Disparities Research. Pediatrics, 2020, 146, .	2.1	17
18	Morphological and functional platelet abnormalities in Berkeley sickle cell mice. Blood Cells, Molecules, and Diseases, 2008, 41, 109-118.	1.4	16

#	Article	IF	Citations
19	Review and Update on Evidence-Based Surgical Treatment Recommendations for Nonmelanoma Skin Cancer. Dermatologic Clinics, 2019, 37, 425-433.	1.7	16
20	Melanoma and Racial Health Disparities in Black Individualsâ€"Facts, Fallacies, and Fixes. JAMA Dermatology, 2021, 157, 1031.	4.1	15
21	Tissue Inhibitor of Metalloproteinase 1 Is Preferentially Expressed in Th1 and Th17 T-Helper Cell Subsets and Is a Direct Stat Target Gene. PLoS ONE, 2013, 8, e59367.	2.5	15
22	Association Between Method of Prescribing and Primary Nonadherence to Dermatologic Medication in an Urban Hospital Population. JAMA Dermatology, 2017, 153, 49.	4.1	14
23	A State-of-the-Art Review Highlighting Medical Overuse in Dermatology, 2017-2018. JAMA Dermatology, 2019, 155, 1410.	4.1	14
24	Characteristics of Medicare Payments to Dermatologists in 2013. JAMA Dermatology, 2017, 153, 95.	4.1	12
25	Representation and misdiagnosis of dark skin in a large-scale visual diagnostic challenge. Journal of the American Academy of Dermatology, 2022, 86, 950-951.	1.2	12
26	Screening for Melanoma in Men: a Cost-Effectiveness Analysis. Journal of General Internal Medicine, 2020, 35, 1175-1181.	2.6	10
27	Trends in Medicare spending on topical immunomodulators and chemotherapies. Journal of the American Academy of Dermatology, 2018, 78, 173-175.	1.2	9
28	Gene Expression Profile Testing for Thin Melanoma. JAMA Dermatology, 2020, 156, 837.	4.1	9
29	Should we refer to skin as â€œethnic?â€. Journal of the American Academy of Dermatology, 2017, 76, 1224-1225.	1.2	8
30	Impact of Industry Payments on Prescribing Patterns for Tumor Necrosis Factor Inhibitors Among Medicare Beneficiaries. Journal of General Internal Medicine, 2019, 34, 176-178.	2.6	8
31	Reconsidering Named Honorifics in Medicineâ€"the Troubling Legacy of Dermatologist Albert Kligman. JAMA Dermatology, 2021, 157, 153.	4.1	8
32	UV Exposure and the Risk of Keratinocyte Carcinoma in Skin of Color. JAMA Dermatology, 2022, 158, 542.	4.1	8
33	Surgical re-excision vs. observation for histologically dysplastic naevi: a systematic review of associated clinical outcomes. British Journal of Dermatology, 2018, 179, 590-598.	1.5	7
34	Eliminating Copayments for Skin Cancer Screeningâ€"A Public Health Policy With Insufficient Evidence. JAMA Dermatology, 2019, 155, 1339.	4.1	7
35	Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment. Journal of the American Academy of Dermatology, 2019, 80, 577-578.	1.2	7
36	Medicare Part D payments for brand and generic drugs prescribed by dermatologists. Journal of the American Academy of Dermatology, 2018, 79, 575-577.	1.2	4

#	Article	IF	Citations
37	Prescription-level factors associated with primary nonadherence to dermatologic medications. Journal of Dermatological Treatment, 2018, 29, 300-304.	2.2	4
38	Observation of Moderately Dysplastic Nevi With Positive Margins. JAMA Dermatology, 2018, 154, 1387.	4.1	4
39	Association of surgical interval and survival among hospital and non-hospital based patients with melanoma in North Carolina. Archives of Dermatological Research, 2021, 313, 653-661.	1.9	4
40	Association of Tumor Characteristics With Insurance Type Among Patients Undergoing Mohs Micrographic Surgery for Nonmelanoma Skin Cancer. JAMA Dermatology, 2022, 158, 919.	4.1	4
41	Pediatric-Onset Refractory Lupus Erythematosus Panniculitis Treated With Rituximab. , 2021, 108, E44-E46.		3
42	Should Recommendations for Cancer Screening Differentiate on Race?. , 2022, 1, .		3
43	Active Comparator Trial Designs Used to Promote Development of Innovative New Medications. , 2020, 106, E4-E6.		2
44	Decision Curve Analysis and the Net Benefit of Novel Tests. JAMA Dermatology, 2022, 158, 684.	4.1	2
45	A Missed Opportunity to Discuss Racial and Gender Bias in Dermatology. JAMA Dermatology, 2017, 153, 110.	4.1	1
46	Translating Administrative Health Care Data to Treatment Decisions in Dermatology. JAMA Dermatology, 2018, 154, 1256.	4.1	1
47	Toward automated assessment of mole similarity on dermoscopic images. Journal of Medical Imaging, 2021, 8, 014506.	1.5	1
48	Distance to pharmacy and risk of medication primary nonadherence. Dermatology Online Journal, 2018, 24, .	0.5	1
49	Billing Patterns and Geographic Distribution of Dermatologist-Dermatopathologists in the US From 2013 to 2017. JAMA Dermatology, 2022, 158, 581.	4.1	1
50	Perineal Rash and Perianal Pain. Journal of Emergency Medicine, 2015, 49, e59-e60.	0.7	0
51	Mohs Micrographic Surgery Use in the United States Based on Medicare Dataâ€"Reply. JAMA Dermatology, 2017, 153, 835.	4.1	0
52	Treatment of Non-melanoma Skin Cancer in the Elderly. Current Geriatrics Reports, 2018, 7, 216-221.	1.1	0
53	Evaluation of the Merits and Limitations of Evidence-Based Medicineâ€"Reply. JAMA Dermatology, 2020, 156, 925.	4.1	0
54	Changes in Use of Radiotherapy Among Dermatologists From 2013 to 2017. JAMA Dermatology, 2021, 157, 322.	4.1	0

#	Article	IF	Citations
55	Concordance between dermatologist self-reported and industry-reported interactions at a national dermatology conference. Cutis, 2020, 105, 203-208;E1.	0.3	0
56	Differentiating Between Lead-Time Bias and True Survival Benefits When Discussing Racial and Ethnic Disparities in Melanomaâ€"Reply. JAMA Dermatology, 2022, , .	4.1	0
57	Risk of nonâ€acral cutaneous melanoma after the diagnosis of acral melanoma. British Journal of Dermatology, 2022, , .	1.5	0
58	An Antiracist Framework for Racial and Ethnic Health Disparities Research. , 2022, , 156-158.		0